




































Alzheimer’s disease (AD) is a fatal brain disease 
characterized by neuronal inflammation, neuronal cell 
loss, and decline of memory and recognition [1]. 
However, as the leading cause for death of dementia, 
the pathogenesis of AD is still far from being 
understood. Two hall marks of AD are senile plaques 
(SPs), which are mainly composed of β-amyloid peptide 
(Aβ) depositing outside of neuron bodies, and 
neurofibrillary tangles (NFTs), which are aggregates of 
hyperphosphorylated tau proteins that bind to 
microtubules within the neurons [1].  
 
Among all hypotheses for the pathogenesis of AD, cell 
cycle re-entry has been supported by studies from 
transgenic mice and patients with  AD [2-5].  Increasing  
 
 



































evidence points to the cell cycle as a new therapeutic 
target for AD [6]. Neurons in the adult central neuronal 
system are terminally differentiated, meaning that they 
are arrested in the G0 state of the cell cycle. During AD 
progression, under continued stimuli of proliferation, 
neurons attempt to exit G0 and re-enter the cell cycle, as 
indicated by elevation of cell cycle markers and 
completion of DNA replication [5]. However, 
terminally differentiated neurons lack the ability to 
complete the cell cycle and therefore re-activation of the 
cell cycle machinery will lead to cell death [7]. Thus, 
one urgent task is to find the stimuli which lead and 
propel the neuronal cell cycle re-entry and eventually 
cell death. 
 
Genetic and biochemical experiments have shown that 
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pivotal regulator of the cell cycle [8]. Expression of 
Plk1 is tightly regulated during the cell cycle; Plk1 is 
detected at S phase, continues to increase at G2 phase 
and reaches a peak during mitosis [9]. Consistent with 
its protein expression level, Plk1 has been shown to be 
essential for G2/M checkpoint recovery, mitotic entry, 
centrosome maturation and assembly of bipolar spindles 
[8]. In addition to multiple mitotic functions, several 
recent reports have established a link between Plk1 and 
DNA replication [10-12]. Significantly, Plk1 is highly 
present in susceptible hippocampal and cortical neurons 
of AD patients but not age-matched controls [13].  
 
In this study, we show that Plk1 activity is significantly 
elevated in the hippocampal tissues of AD patients, as 
indicated by the increased phosphorylation level of 
p150
Glued, an established Plk1 substrate [14]. To further 
dissect the role of Plk1 in AD, we demonstrate that Plk1 
protein and its kinase activity are elevated during the 
neuronal cell-cycle re-entry process induced by Aβ 
treatment. Furthermore, depletion of Plk1 reduces Aβ-
induced neuronal cell death. These results indicate the 
involvement of Plk1-associated kinase activity in the 




In adult tissues, Plk1 is not present or present at a very 
low level in non-proliferating tissue cells, such as brain, 
pancreas and heart [9]. However, Plk1 can be detected 
in brain tissues of patients with AD [13]. But whether 
Plk1 is involved in the pathogenesis of AD is still 
unknown. Considering the fact that Plk1 regulates cell 
cycle through phosphorylation of its substrates, we 
examined brain samples of AD patients by 
immunocytochemistry staining of phospho-Ser179-
p150
Glued. p150
Glued, the largest subunit of the 
dynein/dynactin motor complex, plays important roles 
in many cellular processes, including neurodegeneration 
[15]. Our published work demonstrated that Plk1-
mediated phosphorylation of p150
Glued at Ser179 starts 
at interphase and that the phosphorylation event 
facilitates nuclear envelope breakdown at prophase of 
the cell cycle [14]. Phosphorylation of S179-p150
Glued 
was detected in brain tissues of AD cases but not age-
matched controls, indicating that not only Plk1 protein 
is expressed but its kinase activity is also activated in 
AD patient brains (Figure 1).   
 
To further investigate the role of Plk1 in AD formation, 
we established an in vitro cell culture system to mimic 
aberrant neuronal cell cycle re-entry during the 
pathogenesis of AD. Rat pheochromocytoma PC12 cells 































nerve growth factor (NGF) treatment, mimicking the 
terminally differentiated neurons in adult brains [16]. 
Then Aβ25-35 was then introduced to induce cell cycle 
re-entry and eventually neuronal cell death [1]. We first 
monitored Plk1 protein expression level during the 
process. As expected, Plk1 protein level was abolished 
after NGF treatment, indicating that PC12 cells were 
enriched at G0 phase after NGF treatment. Upon Aβ25-35 
treatment-induced cell cycle re-entry, Plk1 protein level 
was elevated. When PC12 cells were treated with BI 
2536, a Plk1 inhibitor, together with Aβ25-35, a slight 
decrease in Plk1 protein level was observed possibly 
due to the slowed progression of cell cycle re-entry 
(Figure 2A). We also performed in vitro IP/kinase 
assays to test Plk1-associated kinase activity in our 
system. As shown in Figure 2B, Plk1 kinase activity 
mirrors Plk1 protein level in our system (Figure 2B). 
These results indicate that Plk1 is expressed and 
activated during the cell cycle re-entry of neuronal cells.   
 
To evaluate the significance of elevated Plk1 level 
during the cell cycle re-entry process, Plk1 activity was 
inhibited by BI 2536 treatment. Inhibition of Plk1 
significantly decreased Aβ-induced neuronal cell death, 
indicating that Plk1 promotes Aβ-induced neuronal cell 
 
Figure  1.  An  increased  phosphorylation  level  of
p150
Glued  in  AD  neurons.  Hippocampal  tissues  of  AD
patients  or  age‐matched  controls  were  subjected  to
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showed that DNA synthesis was reduced after BI 2536 
treatment, suggesting that Plk1 inhibition prevents Aβ-
induced cell cycle re-entry (Figure 3B). Since BI 2536 
might also partially inhibit Plk2 and Plk3 activities due 

















































RNAi to test whether Plk1 promotes neuronal cell cycle 
re-entry and consequent cell death. Knockdown 
efficiency of Plk1 protein was demonstrated by Western 
blotting (Figure 4A). Knock-down of Plk1 significantly 
prevented cell cycle re-entry (Figure 4C) and decreased 
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Plk1 is one of the best characterized Ser/Thr protein 
kinases. Genetic and biochemical studies have shown 
that Plk1 plays critical roles in many aspects of the cell 
cycle, such as DNA replication, G2 DNA damage 
recovery and mitotic entry [8, 10]. Consistent with these 
functions, the protein expression level of Plk1 starts to 
increase in S phase and peaks at G2/M [9]. Our 
published data have shown that Plk1 phosphorylates 
p150
Glued at Ser179 during G2 phase [14]. Significantly, 
p150
Glued is involved in neurodegenerative diseases [15]. 
In this study, we reported an increased level of 
phosphorylation of p150
Glued-S179 in AD brains 
compared to age-matched controls, indicating that the 
elevated Plk1 protein in the neurons of AD patients is 
activated and able to phosphorylate its known substrates. 
Furthermore, our finding suggests that Plk1 might be a 
feasible therapeutic target for AD, as several small-
molecule inhibitors of Plk1 are under clinical trials [8].   
 


































an in vitro cell culture model to mimic the neuronal cell 
cycle re-entry during the pathogenesis of AD.  We 
found that Plk1 is expressed and activated during the 
neuronal cell-cycle re-entry process induced by Aβ-
treatment. Aberrant cell cycle re-entry has been 
characterized as an early event of AD progression [1], 
and several cell cycle markers, such as cyclin D, cdk4, 
cyclin B, phospho-H3 and p27, are present in terminally 
differentiated AD neurons [18]. However, these proteins 
are detected in different spatial patterns as they 
normally do [19-21], supporting the notion that these 
cell cycle regulators might have novel functions during 
the pathogenesis of AD. For that reason, we 
acknowledge that we cannot exclude the possibility that 
Plk1 might also have a novel function in AD. However, 
the IHC staining data of phospho-p150
Glued-S179 
suggest that Plk1 kinase activity is activated in AD and 
that Plk1 phosphorylates its documented substrates in 
normal cell cycle. Significantly, our data demonstrate 
that Plk1 inhibition or depletion slowed cell cycle 
progression (Figure 3B, 4B) and reduced Aβ-induced 
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shown to be involved in age-related diseases, such as 
Alzheimer’s disease.  Two of the downstream targets of 
mTOR are the ribosomal p70S6 kinase (p70S6K) and 
the 4E-binding protein 1 (4E-BP1) [22].  Recent study 
shows that Plk1 inhibition decreases phosphorylation of 
these two mTOR downstream targets, thus inhibits 
mTOR pathway [23].  And inhibition of mTOR 
pathway slows down aging thus age-related diseases in 
varies species [22].  Plk2, which is another polo-like 
kinase member, has also been linked to mTOR pathway 
regulation [24].  Our findings support and further 
suggest that prevention of cell cycle re-entry by 
inhibition of Plk1 might be a promising strategy for AD 
therapeutics. Understanding the initiation factor of 
neuronal cell cycle re-entry will help open a path to 
pursue the prevention or cure of AD. 
 
MATERIAL AND METHODS 
 
Cell culture. Rat pheochromocytoma PC 12 cells were 
cultured in RPMI-1640 medium (ATCC, 30-2001) with 
10% of heat-inactivated horse serum (Sigma, H1138) 
and 5% of fetal bovine serum (Atlanta, S11550). To 
induce differentiation of PC12 cells, we seeded the cells 
on the plates coated with Poly-L-lysine (Sigma, P4707) 
for 24h, then replaced the complete culture medium 
with differentiating medium (RPMI-1640 supplemented 
with 1% heat-inactivated horse serum and 100ng/mL 
Nerve Growth Factor-7S) with medium change every 
other day. Cells were treated for 3 days to be 
differentiated into neuronal-like cells [16]. 
 
Aβ. Previous reports have shown that Aβ25-35 and Aβ1-40 
have a comparable biological effect on inducing cell 
death [25], thus Aβ25-35 was used in this study. Aβ25-35 
(Sigma, A4559) was dissolved in sterile water to a stock 
concentration of 1 mM. To prepare aggregated Aβ 
peptides, stock Aβ  was mixed with same amount of 
PBS, and incubated for 3 days at 37°C. Cells were 
treated at 25 μM for 24 h for various assays.     
 
Kinase assay. For In vitro IP/kinase assays, total cell 
extracts were immunoprecipitated (IPed) with Plk1 
antibodies (Santa Cruz, sc-17783), and the IPed 
proteins were subjected to kinase assays with GST-
Orc2 as substrate. Kinase assays were performed in 
TBMD buffer (50 mM Tris, pH 7.5, 10 mM MgCl2, 5 
mM dithiothreitol, 2 mM EGTA, 0.5 mM sodium 
vanadate, 20 mM p-nitrophenyl phosphate) 
supplemented with 125 µM ATP and 10 µCi of [γ-
32P]ATP at 30°C for 30min. After the reaction 
mixtures were resolved by  SDS-PAGE,  the  gels were  
stained with Coomassie Brilliant blue, dried, and 
subjected to autoradiography.  
RNA interference.  To specifically deplete Plk1, 
lentiviruses were generated with the targeting rat 
sequences AGATCACTCTCCTCAACTATT and 
CAACAAAAGTGGAATATGAAG [26]. Lentivirus 
infection was performed in the presence of Polybrene 
(10 µg/ml) and HEPES (10 mM). 
 
BrdU labeling assay.  BrdU-labeling assays were 
performed with a kit from Roche according to the 
manufacturer’s instructions.   
 
Cell death assay. Cells were incubated with 10 μg/ml 
propidium iodide (PI) for 15 min at 37°C and washed 
with PBS, followed by DAPI staining.  
 
Western blotting. Cell lysates were resolved by SDS-
PAGE and detected by Western blotting with antibodies 
against β-actin (Sigma, A5441) and Plk1 (Santa Cruz, 
sc-17783). 
 
Tissue. Tissues were prepared and stained as described 
previously [5]. 
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